Table 1

Demographics and clinical characteristics of patients at the time of sampling

Featuren=321
Female sex, n (%)299 (93.1)
Age (years), mean±SD46.7±13.6
Disease duration (years), mean±SD14.7±10.0
Low complement, n (%)157 (48.9)
Anti-dsDNA positivity, n (%)126 (39.3)
Musculoskeletal involvement, n (%)48 (14.9)
Renal involvement, n (%)66 (20.6)
Mucocutaneous involvement, n (%)161 (50.2)
CNS involvement, n (%)26 (8.1)
Serositis, n (%)7 (2.3)
Leucopenia, n (%)54 (16.8)
Thrombocytopenia, n (%)21 (6.5)
PGA (0–3), mean±SD0.5±0.5
SLEDAI-2K, mean±SD6.2±5.6
cSLEDAI, mean±SD4.6±5.4
DORIS remission, n (%)56 (17.4)
LLDAS, n (%)131 (40.8)
Prednisone use, n (%)146 (45.5)
HCQ use, n (%)231 (72.0)
Immunosuppressants, n (%)106 (33.1)
 MMF, n (%)28 (8.7)
 MTX, n (%)19 (5.9)
 AZA, n (%)30 (9.3)
 CNIs, n (%)2 (0.1)
 Not specified, n (%)27 (29.0)
  • AZA, azathioprine; CNIs, calcineurin inhibitors; CNS, central nervous system; cSLEDAI, clinical SLEDAI-2K (excluding the serological descriptors); DORIS, definitions of remission in systemic lupus erythematosus; HCQ, hydroxychloroquine; LLDAS, lupus low disease activity state; MMF, mycophenolate mophetil; MTX, methotrexate; PGA, Physician Global Assessment; SLEDAI-2K, systemic lupus erythematosus disease activity index 2000.